| Serial Number | 87884008 |
| Word Mark | BAUSCH HEALTH |
| Filing Date | Thursday, April 19, 2018 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, February 7, 2023 |
| Registration Number | 6974682 |
| Registration Date | Tuesday, February 7, 2023 |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, November 5, 2019 |
| Goods and Services | Providing on-line publications in the nature of newsletters, pamphlets and bulletins in the field of health issues; newsletters, articles, informational brochures and web-based tools |
| Goods and Services | cardiovascular system; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, hepatologicalrespiratory, neurological, respiratory, neurological, hormonal, psychiatric and immune system related diseases and disorders; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations, namely, immunomodulators; anticholinesterase preparation for the prevention, treatment and alleviation of neurological disorders; Vaginally administered metronidazole gel for use in the treatment of vaginal disorders; intravenous preparations for the treatment of hyperammonemia of all origins; Skin patch for delivering nitroglycerin to a medical patient; anticonvulsants; pharmaceutical preparations and substances for the prevention, treatment and alleviation of stress; pharmaceutical preparations and substances for the prevention, treatment and alleviation of diabetes; pharmaceutical preparations and substances for controlling insulin levels; pharmaceutical preparations and substances for the prevention, treatment and alleviation of hypertension; pharmaceutical preparations and substances for the prevention, treatment and alleviation of angina; pharmaceutical preparations and substances for the cessation of smoking; pharmaceutical preparations and substances for the prevention and treatment of sexually transmitted diseases; pharmaceutical preparations and substances for the prevention and treatment of herpes; pharmaceutical preparations and substances for the prevention, treatment and alleviation of sleep disorders; pharmaceutical preparations and substances for the prevention, treatment and alleviation of acute myocardial infarctions; pharmaceutical preparations and substances for the prevention, treatment and alleviation of symptomatic congestive heart failure; pharmaceutical preparations and substances for the prevention, treatment and alleviation of asymptomatic left ventricular dysfunction; pharmaceutical preparations and substances, namely, fibrinolytic or thrombolytic agents; pharmaceutical preparations and substances for the prevention, treatment and alleviation of pain and inflammation, namely, anti-inflammatories and pain relief medication; pharmaceutical preparations and substances for the prevention, treatment and alleviation of migraines; Pharmaceutical preparations and substances for the treatment of epilepsy, seizures and neurological and psychological diseases and disorders; Medicines and medicinal preparations for human purposes, namely, to support treatment of hemorrhoids, chronic venous insufficiency and lymphedema; sanitary preparations for medical purposes; pharmaceutical preparations to support treatment of hemorrhoids, chronic venous insufficiency and lymphedema; homeopathic pharmaceutics for use in support treatment of hemorrhoids, chronic venous insufficiency and lymphedema and vitamin preparations, all in the form of tablets or powder or soft gelatin capsules or hard gelatin capsules; pharmaceutical preparations and substances for the prevention and treatment of disorders, diseases, conditions and ailments of the cardio-vascular system; pharmaceutical preparations and substances for the prevention and treatment of hypertension; Pharmaceutical preparations for the treatment of nausea, emesis; Acetaminophen sold as an analgesic for the relief of pain; Pharmaceutical products, namely, lipid and triglyceride reducing agents for use in the treatment of cardiovascular and heart disease; Diuretic preparations; pharmaceutical preparations and substances for the prevention, treatment and alleviation of pain; anti-depressants; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the cardiovascular system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of Parkinson's disease; pharmaceutical preparations and substances for the prevention, treatment and alleviation of Huntington's disease; pharmaceutical preparations and substances for the prevention, treatment and alleviation of amyotrophic lateral sclerosis; pharmaceutical preparations and substances for the prevention, treatment and alleviation of Alzheimer's disease; pharmaceutical preparations and substances for the prevention, treatment and alleviation of Tourette Syndrome; pharmaceutical preparations and substances for the prevention, treatment and alleviation of epilepsy; pharmaceutical preparations and substances for the prevention, treatment and alleviation of multiple sclerosis; pharmaceutical preparations and substances for the prevention, treatment and alleviation of cardio-pulmonary disorders, diseases, conditions, and ailments; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions, and ailments of the circulatory system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of hypertension, high blood pressure, heart failure and ventricular dysfunction; pharmaceutical preparations and substances for the prevention, treatment and alleviation of viral and infectious diseases; pharmaceutical preparations and substances for the prevention, treatment and alleviation of central nervous system disorders, diseases, conditions and ailments, namely, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, encephalitis, cerebral palsy, insomnia, mood disorders, bipolar disorder, seizure disorders; pharmaceutical preparations and substances, namely, fibrinolytic or thrombolytic agents; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the respiratory system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the endocrine system; pharmaceutical preparations for the treatment of immunologic diseases, namely, auto immune motility diseases, immunologic deficiency syndromes, auto immune diseases, Acquired Immune Deficiency Syndrome (AIDS), hypersensitivity, allergies, tumors of the immunological organs; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the musculoskeletal system, namely, bone diseases and bone degenerative conditions; pharmaceutical preparations and substances for the prevention, treatment and alleviation of migraines; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations and substances for the treatment of polycystic ovary syndrome; pharmaceutical preparations and substances for the treatment of infertility; pharmaceutical preparations and substances for the treatment of diabetes; pharmaceutical preparations and substances for the treatment of heart disease; pharmaceutical preparations and substances for the treatment of pain; pharmaceutical preparations and substances for the treatment of cardiovascular disease; pharmaceutical preparations and substances for the treatment of depression and social anxiety; pharmaceutical preparations and substances for the treatment of insomnia; pharmaceutical preparations and substances for the treatment of sleep disorders; pharmaceutical preparations and substances for the treatment of migraine and neurological disorders; Pharmaceutical preparations for the treatment of cancer, neurological and dermatological disorders; pharmaceutical preparations for the treatment of myasthenia gravis, depression, mood/anxiety conditions, solar keratoses and cancer; antidepressants; tranquilizers; nasal spray preparations; Pharmaceutical preparations for the treatment of neuromuscular conditions; Pharmaceutical preparations, namely, retinoids, for the treatment of skin related diseases, cancer and precancerous conditions, and disorders related to the modulation of apoptosis; vitamin supplement distributed by prescription only; pharmaceutical preparations, namely, an oral glucose gel for the treatment of low blood sugar; pharmaceutical preparation for the treatment of headaches; pharmaceutical preparations;, namely, diazepam rectal gel; Methyltestosterone for use in the treatment of hormone deficiencies; medicated skin lotion for the relief of itch caused by insect bites, eczema, sunburn and poison ivy; Preparations and substances for the relief of anorectal discomfort, inflammation, and irritation; hemorrhoidal suppositories; Pharmaceutical preparations for the treatment of irritable bowel syndrome; Drugs to treat opioid-induced constipation; Psychotropic preparations; Cough medicine in the nature of saline solution, namely, a spray for nasal dryness due to allergies, cold and flu; Dermotherapeutic preparation for use in the treatment of obesity; pharmaceutical preparations for the treatment of neurological disorders and movement disorders; antiobesity agent in the nature of a pharmaceutical preparation; and alleviation of pain; anti-depressants; pharmaceutical preparations and substances for the prevention, treatment and alleviation of anxiety, depression, depressive disorders and mental illness; tranquilizers and sedatives; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments |
| Section 2(f) Limitation Statement | as to "BAUSCH" |
| Goods and Services | Providing a website featuring information and advice in the field of health issues |
| Disclaimer with Predetermined Text | "HEALTH" |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, April 27, 2018 |
| Primary Code | 005 |
| First Use Anywhere Date | Wednesday, March 12, 2014 |
| First Use In Commerce Date | Wednesday, March 12, 2014 |
| International Class | 041 - Education; providing of training; entertainment; sporting and cultural activities. |
| US Class Codes | 100, 101, 107 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, April 27, 2018 |
| Primary Code | 041 |
| First Use Anywhere Date | Wednesday, March 12, 2014 |
| First Use In Commerce Date | Wednesday, March 12, 2014 |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, April 27, 2018 |
| Primary Code | 044 |
| First Use Anywhere Date | Wednesday, March 12, 2014 |
| First Use In Commerce Date | Wednesday, March 12, 2014 |
| Party Name | Bausch & Lomb Incorporated |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 03 - Corporation |
| Address | Rochester, NY 14609 |
| Party Name | Bausch & Lomb Incorporated |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Rochester, NY 14609 |
| Party Name | Bausch & Lomb Incorporated |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Rochester, NY 14609 |
| Event Date | Event Description |
| Wednesday, December 6, 2023 | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY |
| Tuesday, February 7, 2023 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Tuesday, February 7, 2023 | REGISTERED-PRINCIPAL REGISTER |
| Friday, January 6, 2023 | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
| Thursday, January 5, 2023 | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
| Tuesday, January 3, 2023 | STATEMENT OF USE PROCESSING COMPLETE |
| Sunday, January 1, 2023 | USE AMENDMENT FILED |
| Sunday, January 1, 2023 | TEAS STATEMENT OF USE RECEIVED |
| Wednesday, December 28, 2022 | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY |
| Wednesday, December 21, 2022 | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY |
| Wednesday, December 14, 2022 | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY |
| Monday, October 10, 2022 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Monday, October 10, 2022 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Monday, October 10, 2022 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Monday, October 10, 2022 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Monday, October 10, 2022 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Tuesday, July 12, 2022 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Monday, July 11, 2022 | SOU EXTENSION 5 GRANTED |
| Tuesday, June 28, 2022 | SOU EXTENSION 5 FILED |
| Monday, July 11, 2022 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Tuesday, June 28, 2022 | SOU TEAS EXTENSION RECEIVED |
| Thursday, June 23, 2022 | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY |
| Wednesday, March 9, 2022 | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY |
| Tuesday, November 9, 2021 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Sunday, November 7, 2021 | SOU EXTENSION 4 GRANTED |
| Sunday, November 7, 2021 | SOU EXTENSION 4 FILED |
| Sunday, November 7, 2021 | SOU TEAS EXTENSION RECEIVED |
| Saturday, October 16, 2021 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Saturday, October 16, 2021 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Saturday, October 16, 2021 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Tuesday, June 1, 2021 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Sunday, May 30, 2021 | SOU EXTENSION 3 GRANTED |
| Sunday, May 30, 2021 | SOU EXTENSION 3 FILED |
| Sunday, May 30, 2021 | SOU TEAS EXTENSION RECEIVED |
| Thursday, December 3, 2020 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Tuesday, December 1, 2020 | SOU EXTENSION 2 GRANTED |
| Tuesday, December 1, 2020 | SOU EXTENSION 2 FILED |
| Tuesday, December 1, 2020 | SOU TEAS EXTENSION RECEIVED |
| Wednesday, November 25, 2020 | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY |
| Tuesday, May 19, 2020 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Friday, May 15, 2020 | SOU EXTENSION 1 GRANTED |
| Friday, May 15, 2020 | SOU EXTENSION 1 FILED |
| Friday, May 15, 2020 | SOU TEAS EXTENSION RECEIVED |
| Monday, May 11, 2020 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Monday, May 11, 2020 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Monday, May 11, 2020 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Monday, May 11, 2020 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Monday, May 11, 2020 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Tuesday, December 31, 2019 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Tuesday, November 5, 2019 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, November 5, 2019 | PUBLISHED FOR OPPOSITION |
| Wednesday, October 16, 2019 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Saturday, September 28, 2019 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Saturday, September 28, 2019 | EXAMINER'S AMENDMENT ENTERED |
| Saturday, September 28, 2019 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Saturday, September 28, 2019 | EXAMINERS AMENDMENT E-MAILED |
| Saturday, September 28, 2019 | EXAMINERS AMENDMENT -WRITTEN |
| Saturday, September 7, 2019 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, September 6, 2019 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, September 6, 2019 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Friday, March 8, 2019 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Friday, March 8, 2019 | NON-FINAL ACTION E-MAILED |
| Friday, March 8, 2019 | NON-FINAL ACTION WRITTEN |
| Friday, February 15, 2019 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, February 14, 2019 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, February 14, 2019 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Thursday, February 14, 2019 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Thursday, February 14, 2019 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Wednesday, August 15, 2018 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Wednesday, August 15, 2018 | NON-FINAL ACTION E-MAILED |
| Wednesday, August 15, 2018 | NON-FINAL ACTION WRITTEN |
| Thursday, August 9, 2018 | ASSIGNED TO EXAMINER |
| Friday, July 13, 2018 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Friday, July 13, 2018 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Friday, April 27, 2018 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Monday, April 23, 2018 | NEW APPLICATION ENTERED |